Standard BioTools Inc.
NasdaqGS:LAB Rapport sur les actions
Capitalisation boursière : US$763.1m
Standard BioTools Croissance future
Future contrôle des critères 1/6 Standard BioTools devrait augmenter ses bénéfices et son chiffre d'affaires de 57.9% et de 14.7% par an respectivement. Le BPA devrait croître de de 64.1% par an. Le rendement des capitaux propres devrait être -11.9% dans 3 ans.
Informations clés
57.9%
Taux de croissance des bénéfices
64.1%
Taux de croissance du BPA
Life Sciences croissance des bénéfices 18.8% Taux de croissance des recettes 14.7% Rendement futur des capitaux propres -11.9% Couverture par les analystes Low
Dernière mise à jour 31 Oct 2024
Mises à jour récentes de la croissance future
Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024 Nov 02
Consensus revenue estimates decrease by 15% Aug 07
No longer forecast to breakeven Aug 02
Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024 Aug 02
Forecast to breakeven in 2026 Jul 25
Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024 May 10
Afficher toutes les mises à jour Standard BioTools Inc. Announces the Appointment of Alex Kim as Chief Financial Officer, Effective November 11, 2024
Standard BioTools Inc. Reiterates Revenue Guidance for Full Year 2024 Nov 02
Third quarter 2024 earnings: EPS and revenues exceed analyst expectations Nov 01
Standard BioTools (NASDAQ:LAB) Has Debt But No Earnings; Should You Worry? Oct 26
Standard BioTools Inc. to Report Q3, 2024 Results on Oct 30, 2024 Oct 16
Market Participants Recognise Standard BioTools Inc.'s (NASDAQ:LAB) Revenues Pushing Shares 33% Higher Sep 14
Consensus revenue estimates decrease by 15% Aug 07
Newsflash: Standard BioTools Inc. (NASDAQ:LAB) Analysts Have Been Trimming Their Revenue Forecasts Aug 05
No longer forecast to breakeven Aug 02
Standard BioTools Inc. Revises Revenue Guidance for the Full Year 2024 Aug 02
New minor risk - Share price stability Aug 01
Second quarter 2024 earnings: EPS and revenues miss analyst expectations Aug 01
Standard BioTools Inc. Announces Chief Financial Officer Changes Aug 01
Revenues Tell The Story For Standard BioTools Inc. (NASDAQ:LAB) As Its Stock Soars 42% Jul 26
Forecast to breakeven in 2026 Jul 25
High number of new and inexperienced directors Jul 25
Standard BioTools Inc. to Report Q2, 2024 Results on Jul 31, 2024 Jul 17
Standard BioTools Inc., Annual General Meeting, Jun 27, 2024 May 24
Standard BioTools Inc. Reaffirms Revenue Guidance for the Fiscal Year 2024 May 10
Standard BioTools Inc. to Report Q1, 2024 Results on May 08, 2024 Apr 27 Standard BioTools Inc. Announces Operational Restructuring Plan Apr 26
Now 21% undervalued Apr 18
Standard BioTools Inc. Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the Boundaries of Tissue Imaging Apr 09
Is It Time To Consider Buying Standard BioTools Inc. (NASDAQ:LAB)? Apr 09
Consensus EPS estimates upgraded to US$0.43 loss Apr 03
Chief Strategy Officer notifies of intention to sell stock Mar 20
Estimating The Fair Value Of Standard BioTools Inc. (NASDAQ:LAB) Mar 06
Forecast to breakeven in 2026 Mar 03
Standard BioTools Inc. Provides Revenue Guidance for the Full Year 2024 Mar 01
New major risk - Financial position Feb 29
Standard BioTools Inc.'s (NASDAQ:LAB) P/S Still Appears To Be Reasonable Feb 17
Standard BioTools Inc. to Report Q4, 2023 Results on Feb 28, 2024 Feb 15
Health Check: How Prudently Does Standard BioTools (NASDAQ:LAB) Use Debt? Jan 12
New major risk - Revenue and earnings growth Jan 09
Standard Biotools Inc. Provides Revenue Guidance for the Fourth Quarter and full year 2023 Jan 09
SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others. Jan 06 SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.
Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Standard BioTools Inc. to Report Q3, 2023 Results on Nov 07, 2023 Oct 26 SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 06
SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction. Oct 05
Is Standard BioTools (NASDAQ:LAB) A Risky Investment? Aug 13
Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind Aug 09
Standard BioTools Inc. to Report Q2, 2023 Results on Aug 08, 2023 Jul 26
High number of new directors Jun 22
Senior VP & CFO recently bought US$194k worth of stock May 24
Standard BioTools Inc. Announces NGS Library Preparation as an Upgrade on the X9 High-Throughput Genomics System May 19 Standard BioTools Inc. Appoints Jeffrey Black as Chief Financial Officer
First quarter 2023 earnings released: US$0.21 loss per share (vs US$0.99 loss in 1Q 2022) May 11
Standard BioTools Inc. Announces Retirement of Gerhard Burbach as Member of the Board of Directors May 05
Chief Financial Officer exercised options and sold US$58k worth of stock Mar 01
Standard BioTools Inc. Provides Earnings Guidance for the Year 2023 Feb 16
Full year 2022 earnings released: US$2.43 loss per share (vs US$0.78 loss in FY 2021) Feb 16
Standard BioTools Inc. to Report Q4, 2022 Results on Feb 14, 2023 Feb 01
Standard Biotools Inc. Appoints Betsy Jensen as Chief Human Resources Officer Jan 04
Standard BioTools Inc. (NasdaqGS:LAB) announces an Equity Buyback for $20 million worth of its shares. Nov 29
Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.18 loss in 3Q 2021) Nov 10
Standard BioTools Inc. to Report Q3, 2022 Results on Nov 08, 2022 Oct 26
Standard BioTools Releases the X9 Real-Time PCR System, Its Most Productive and Flexible High-Capacity Genomics Platform Oct 07
Second quarter 2022 earnings released: US$0.82 loss per share (vs US$0.23 loss in 2Q 2021) Aug 10
Standard BioTools Inc. Reports Impairment Charges for the Second Quarter Ended June 30, 2022 Aug 10
Standard BioTools Inc. to Report Q2, 2022 Results on Aug 08, 2022 Jul 26
Standard BioTools Inc. Announces Resignation of Nicholas Khadder as Senior Vice President, General Counsel and Corporate Secretary Jul 09
Standard Biotools Inc. Announces Resignation of Bradley Kreger, Senior Vice President, Global Operations Jun 29
Standard BioTools Inc.(NasdaqGS:LAB) dropped from Russell Microcap Value Index Jun 26
First quarter 2022 earnings: EPS and revenues exceed analyst expectations May 06
Standard BioTools Inc., Annual General Meeting, Jun 15, 2022 May 02
Price target decreased to US$6.00 Apr 27
Standard BioTools Inc. to Report Q1, 2022 Results on May 05, 2022 Apr 23
Standard Biotools Inc. Launches Hyperion+ Imaging System, the New Standard in High-Plex Spatial Imaging Apr 12
Independent Director exercised options to buy US$80k worth of stock. Apr 06 Fluidigm Corporation Announces Board Changes
Fluidigm Corporation Announces Management Changes Mar 30
Price target decreased to US$6.00 Feb 24
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 19
Fluidigm Corporation: Investment Opportunity Jan 26
Prévisions de croissance des bénéfices et des revenus NasdaqGS:LAB - Estimations futures des analystes et données financières antérieures (USD Millions ) Date Recettes Les revenus Flux de trésorerie disponible Cash from Op Moy. Nombre d'analystes 12/31/2026 229 -33 -9 -1 2 12/31/2025 188 -84 -69 -62 3 12/31/2024 171 -155 -164 -157 3 9/30/2024 156 -171 -149 -143 N/A 6/30/2024 136 -165 -131 -127 N/A 3/31/2024 127 -136 -100 -97 N/A 12/31/2023 106 -75 -46 -43 N/A 9/30/2023 105 -76 -52 -48 N/A 6/30/2023 105 -84 -65 -62 N/A 3/31/2023 97 -131 -86 -82 N/A 12/31/2022 98 -190 -93 -89 N/A 9/30/2022 109 -179 -81 -77 N/A 6/30/2022 112 -163 -66 -62 N/A 3/31/2022 124 -117 -54 -47 N/A 12/31/2021 131 -59 -57 -44 N/A 9/30/2021 137 -68 -64 -41 N/A 6/30/2021 148 -60 -58 -36 N/A 3/31/2021 143 -56 -43 -24 N/A 12/31/2020 138 -53 -28 -15 N/A 9/30/2020 126 -48 -20 -17 N/A 6/30/2020 113 -55 -21 -17 N/A 3/31/2020 115 -55 -23 -19 N/A 12/31/2019 117 -65 -38 -35 N/A 9/30/2019 117 -67 -32 -30 N/A 6/30/2019 120 -69 -31 -30 N/A 3/31/2019 118 -71 -30 -29 N/A 12/31/2018 113 -59 -26 -25 N/A 9/30/2018 108 -55 -24 -24 N/A 6/30/2018 104 -56 N/A -28 N/A 3/31/2018 102 -57 N/A -32 N/A 12/31/2017 102 -61 N/A -24 N/A 9/30/2017 99 -68 N/A -35 N/A 6/30/2017 97 -72 N/A -41 N/A 3/31/2017 101 -73 N/A -40 N/A 12/31/2016 104 -76 N/A -39 N/A 9/30/2016 110 -71 N/A -33 N/A 6/30/2016 117 -61 N/A -32 N/A 3/31/2016 117 -57 N/A -33 N/A 12/31/2015 115 -53 N/A -35 N/A 9/30/2015 117 -51 N/A -34 N/A 6/30/2015 118 -56 N/A -30 N/A 3/31/2015 117 -53 N/A -22 N/A 12/31/2014 116 -53 N/A -23 N/A 9/30/2014 104 -47 N/A -16 N/A 6/30/2014 92 -37 N/A -8 N/A 3/31/2014 82 -28 N/A -11 N/A 12/31/2013 71 -17 N/A -2 N/A
Afficher plus
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: LAB devrait rester non rentable au cours des 3 prochaines années.
Bénéfices vs marché: LAB devrait rester non rentable au cours des 3 prochaines années.
Croissance élevée des bénéfices: LAB devrait rester non rentable au cours des 3 prochaines années.
Chiffre d'affaires vs marché: Le chiffre d'affaires de LAB ( 14.7% par an) devrait croître plus rapidement que le marché US ( 9% par an).
Croissance élevée des revenus: Le chiffre d'affaires de LAB ( 14.7% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: LAB devrait être non rentable dans 3 ans.
Découvrir les entreprises en croissance Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"display-ssr-flag","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}
